LatchBio

LatchBio operates as a bioinformatics infrastructure platform, enabling biopharma R&D teams and commercial solution providers to analyze complex genomics and multi-omics data faster and more cost-effectively. Its core value proposition is unifying fragmented data analysis systems into a single, compliant platform that reduces analysis costs by up to 80% and cuts development timelines. The company has achieved significant traction, trusted by over 4,000 scientists and supporting the bioinformatics platforms of 40+ innovative solution providers, including major partners like GSK and Amgen. LatchBio employs a usage-based pricing model, claiming to save customers over 72% compared to major public clouds like AWS, GCP, and Azure for biological data processing.

A unified, cloud-native SaaS platform for biological data analysis. It features modular components for workflow orchestration (Nextflow-based), scalable compute (Pods), interactive visualization (Plots), and data/metadata management. The platform is FAIR and IND-ready, supports 40+ genomics assays, and can be fully white-labeled by solution providers. It includes an AI Agent (Claude 4.5 Opus) for natural language data interaction.

LatchBio competes in the bioinformatics platform space against generic cloud infrastructure providers (AWS, GCP, Azure), broad commercial platforms like DNAnexus and Seven Bridges, and a multitude of point solutions for specific analysis types (e.g., Partek Flow, Geneious). Its key differentiation is a sharp focus on biology-specific user experience, a white-label strategy for solution providers, and a usage-based pricing model that undercuts raw cloud costs for biological data processing.